Finally, the study highlighted the importance, also from an immunohistochemical point of view, to maintain TFE3 and TFEB-rearranged renal cell carcinoma as distinct entities, as recommended by the forthcoming WHO classification of renal tumors. This evidence concerns the gene TFE3 and renal cell carcinoma.